Failure mode and effects analysis of medication adherence in patients with chronic myeloid leukemia

Hosoya, Kazuhisa; Mochinaga, Sakiko; Emoto, Akiko; Yokoo, Hiromi; Tokushima, Hideaki; Egoshi, Masayoshi; Sueoka‐Aragane, Naoko; Kimura, Shinya

doi:10.1007/s10147-015-0843-2

Cited by 11 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 20 participants were aged between 36-75 years (mean 60.9) and had been diagnosed for [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19] years (mean 6.23). 18 had a partner, all had children (four living at home) and 13 were grandparents.…”

Section: Resultsmentioning

confidence: 99%

“…Yet imatinib is still the most widely used TKI due to cost-effectiveness and acceptable side effects. CML patients with long-lasting sustained CMR, amounting to 10-15% of patients, may be eligible for discontinuation [9,12,16,18,25].…”

mentioning

confidence: 99%

“…As CML is a lowgrade symptom disease, treatment often represents patients' main disease impact [3,10]. Side effects are mostly considered mild to moderate but may include edema, diarrhoea, pleural effusions, nausea, muscosceletal or abdominal pain, rashes, fatigue, or headache [1][2][3][4]7,9,[11][12][13][14][15][16][17][18][19][20][21].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Drivers and Barriers to Medication Adherence in Patients with Chronic Myeloid Leukaemia: A Qualitative Study

Mortensen¹,

Mourek

2017

JHOR

View full text Add to dashboard Cite

With the introduction of tyrosine kinase inhibitors (TKI), patients with chronic myeloid leukemia (CML) have obtained survival rates close to normal. It may appear paradoxical, then, that medication adherence is suboptimal in some health care settings. As the first of its kind, this study aimed to explore drivers and barriers to TKI treatment adherence in Danish CML patients. A literature study informed the design of qualitative interviews with 20 patients, individually and in focus groups, focusing on their disease perceptions of CML, their health-related quality of life (QoL) and medication adherence. The study showed that many participants had previously switched treatment due to lacking efficacy or intolerance but most felt their current disease burden was tolerable. Anxiety might, however, resurface if treatment stopped working or with the occurrence of infections or side effects, creating a state of 'fragile peace'. To these patients, their role functioning -as professionals, spouses, parents and grandparents -was crucial to uphold a positive self-image and meaningful life. Whether treatment enabled or hindered this was thus decisive to their QoL and medication adherence. Our participants expressed high adherence rates with only one having intentionally non-adhered due to side effects and poor QoL. Most participants felt well-informed about CML and treatment and privileged to receive specialised personal care from the public health care system acting to motivate their medication adherence. As a novel finding, this study indicates that the prospect of treatment-free remission may positively affect adherence. We suggest this should be explored in future studies.

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Drivers and Barriers to Medication Adherence in Patients with Chronic Myeloid Leukaemia: A Qualitative Study

Mortensen¹,

Mourek

2017

JHOR

View full text Add to dashboard Cite

show abstract

“…Hosoya et collab. 24 ont utilisé des cotations obtenues par sondage de patients et non par consensus d'experts. Ashley et Armitage 43 ont eu recours à deux modes de cotation, soit celle par consensus et celle par moyenne.…”

Section: Résultatsunclassified

Analyse des modes de défaillance, de leurs effets et de leur criticité dans le circuit du médicament : revue de littérature

Demers

Collin-Lévesque

Boulé

et al. 2019

CJHP

View full text Add to dashboard Cite

RESUMÉ Contexte : L’analyse des modes de défaillance, de leurs effets et de leur criticité (AMDEC) est une méthode d’analyse systématique et proactive des risques permettant de déterminer les défaillances majeures de processus complexes. Objectif : Recenser tous les articles concernant l’utilisation de l’analyse des modes de défaillance et de leurs effets (AMDE), de l’AMDEC et de l’AMDEC en santé (AMDECS) dans le cadre du circuit du médicament. Sources des données, sélection des études et extraction des données : La base de données MEDLINE a été interrogée pour la période de janvier 1990 à janvier 2017. La stratégie de recherche a inclus les études appliquant intégralement ou partiellement la méthode AMDEC et traitant d’un ou de plusieurs volets du circuit du médicament. Une recherche manuelle complémentaire a permis d’inclure les références pertinentes des articles consultés. Synthèse des données : Les chercheurs ont trouvé 171 articles. Ils en ont retenu 39, soit 32 décrivant l’utilisation de l’approche AMDE ou AMDEC et sept décrivant l’utilisation de l’approche AMDECS. Ils ont répertorié de quatre à 378 modes de défaillance, selon les études publiées. Dix des 39 articles font état d’une analyse avant et après la mise en vigueur de mesures correctives. Dans quatre de ces 10 articles, l’analyse a été réalisée de façon théorique, soit avant la mise en vigueur réelle des mesures. À partir des articles retenus, un tableau-synthèse a été élaboré avec les éléments suivants : année de publication, premier auteur, pays, objectif principal, objectifs secondaires, description de la méthode, description des résultats, commentaires. Le tableau-synthèse a permis de commenter l’état d’utilisation des analyses de type AMDEC dans le cadre du circuit du médicament. Conclusions : Cette revue de la littérature a retenu 39 articles publiés ayant utilisé l’approche AMDE, AMDEC ou AMDECS dans le cadre du circuit du médicament. La plupart des études ont utilisé l’approche AMDE ou AMDEC, tandis que l’AMDECS n’était que rarement employée. Seule une minorité des études ont évalué les effets de mesures correctives mises en œuvre. Cette approche permet la cartographie d’un processus de soins, la détermination des modes de défaillance et la priorisation des actions correctives. Il faudrait encourager son usage pour l’évaluation du circuit du médicament.ABSTRACT Background: Failure mode, effects, and criticality analysis (FMECA) is a systematic and proactive risk analysis method to determine major failures in complex processes. Objective: To identify all articles involving the use of failure mode and effects analysis (FMEA), FMECA, or FMECA in health care within the medication use system.Data Sources, Study Selection, and Data Extraction: The MEDLINE database was searched, for the period January 1990 to January 2017. The search included studies using the FMECA method, in part or in full, and dealing with one or several components of the medication use system. The reference lists of articles identified in the initial search were checked manually for additional pertinent references. Data Synthesis: The researchers identified 171 articles, and retained 39 for analysis: 32 describing use of the FMEA or FMECA approach and 7 describing use of the FMECA in health care approach. They identified between 4 to 378 failure modes, according to the published studies. Among the 39 articles, 10 reported a pre- and post-implementation analysis of corrective measures. In 4 of those 10 articles, the analysis was conducted on a theoretical basis, that is, before the corrective measures were actually implemented. Using the articles retained for analysis, a summary table was developed with the following elements: publication year, main author, country, primary objective, secondary objectives, descriptions of both method and results, and comments. The summary table gave the opportunity to comment on the use of the FMECA-type analysis within the medication use system. Conclusions: This literature review included 39 published articles using an FMEA, FMECA, or FMECA in health care approach within the medication use system. Most studies used either the FMEA or the FMECA approach, whereas the FMECA in health care approach was used only rarely. Only a minority of studies assessed the effects of corrective measures that were implemented. This overall approach allows for mapping of a care process, determination of failure modes, and prioriti-zation of corrective measures. Its use for the assessment of the medication use system should be promoted.

show abstract

“…FMEA-FMEA is a quality assurance process that is commonly used to address potential flaws and errors during the design stage of a product's life (Willis, 1992). FMEA is frequently used by manufacturing and medical device investigators and is only now emerging as a tool to evaluate behavioral health interventions (Hosoya et al, 2015;Kawai et al, 1989;Manger et al, 2015;Rienzi et al, 2015;Sorrentino, 2016).…”

Section: Process Map Developmentmentioning

confidence: 99%

A mixed-methods process evaluation of Family Navigation implementation for autism spectrum disorder

Broder‐Fingert

Qin

Goupil

et al. 2018

Autism

View full text Add to dashboard Cite

There is growing interest in Family Navigation as an approach to improving access to care for children with autism spectrum disorder, yet little data exist on the implementation of Family Navigation. The aim of this study was to identify potential failures in implementing Family Navigation for children with autism spectrum disorder, using a failure modes and effects analysis. This mixed-methods study was set within a randomized controlled trial testing the effectiveness of Family Navigation in reducing the time from screening to diagnosis and treatment for autism spectrum disorder across three states. Using standard failure modes and effects analysis methodology, experts in Family Navigation for autism spectrum disorder (n = 9) rated potential failures in implementation on a 10-point scale in three categories: likelihood of the failure occurring, likelihood of not detecting the failure, and severity of failure. Ratings were then used to create a risk priority number for each failure. The failure modes and effects analysis detected five areas for potential "high priority" failures in implementation: (1) setting up community-based services, (2) initial family meeting, (3) training, (4) fidelity monitoring, and (5) attending testing appointments. Reasons for failure included families not receptive, scheduling, and insufficient training time. The process with the highest risk profile was "setting up community-based services." Failure in "attending testing appointment" was rated as the most severe potential failure. A number of potential failures in Family Navigation implementation-along with strategies for mitigation-were identified. These data can guide those working to implement Family Navigation for children with autism spectrum disorder. Article reuse guidelines: sagepub.com/journals-permissions

show abstract

Failure mode and effects analysis of medication adherence in patients with chronic myeloid leukemia

Abstract: These findings suggest that an inadequate medication-taking habit such as careless slips may represent a potential target to improve and maximize adherence in CML patients.

Cited by 11 publications

References 23 publications

Drivers and Barriers to Medication Adherence in Patients with Chronic Myeloid Leukaemia: A Qualitative Study

Drivers and Barriers to Medication Adherence in Patients with Chronic Myeloid Leukaemia: A Qualitative Study

Analyse des modes de défaillance, de leurs effets et de leur criticité dans le circuit du médicament : revue de littérature

A mixed-methods process evaluation of Family Navigation implementation for autism spectrum disorder

Contact Info

Product

Resources

About